AI Article Synopsis

  • Microdialysis is the primary method for measuring drug levels in the brain of living animals, but traditional quantitative techniques face significant challenges in accuracy and require many animals.
  • The dynamic no-net-flux (DNNF) method has been seen as a solution but demands high precision and can produce complex data.
  • A modified ultraslow microdialysis approach enhances recovery rates and simplifies the process, showing promise in measuring CNS compound levels effectively with fewer animals, making it easier to study drug penetration through the blood-brain barrier.

Article Abstract

The only method to quantify free extracellular levels of drugs in the brain of living animals is microdialysis. However, quantitative microdialysis has been hampered by methodological issues for decades. The problems arise from the need to establish the in vivo recovery for appropriate quantitation. In dealing with these issues the "dynamic no-net-flux" (DNNF) method seemed to be the experimental method of choice. Major disadvantages were, however, the need for a very high degree of bioanalytical precision and accuracy and the need for a large number of animals. Moreover, today we know that the experimental data are not always straightforward. To improve robustness and practicality of quantitative microdialysis sampling we modified the ultraslow microdialysis approach. Ultraslow microdialysis uses very low microdialysis flow rates (<200 nl/min) which increase recovery (both in vivo and in vitro) to over 90%. However, new practical issues arise when attempting to work with these flow rates. The resulting very low volumes and long lag times make this method very impractical for general application. In the modified version, addition of a carrier flow after the dialysis process has been completed, which negates the problems of long lag times and low volumes. The resulting dilution of the dialysis sample concentration can simply be mathematically corrected. In the current study we measured the free brain levels of two CNS compounds using the classic DNNF and the new modified ultraslow dialysis method. Modified ultraslow microdialysis was shown to generate robust data with the use of only small numbers of rats. The method is a promising tool for common straightforward screening of blood-brain barrier penetration of compounds into the brain.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneumeth.2008.12.010DOI Listing

Publication Analysis

Top Keywords

quantitative microdialysis
12
ultraslow microdialysis
12
modified ultraslow
8
microdialysis
7
microdialysis modified
4
microdialysis direct
4
direct rapid
4
rapid reliable
4
reliable determination
4
determination free
4

Similar Publications

Since its first introduction, levodopa has remained the cornerstone treatment for Parkinson's disease. However, as the disease advances, the therapeutic window for levodopa narrows, leading to motor complications like fluctuations and dyskinesias. Clinicians face challenges in optimizing daily therapeutic regimens, particularly in advanced stages, due to the lack of quantitative biomarkers for continuous motor monitoring.

View Article and Find Full Text PDF
Article Synopsis
  • Eribulin is a microtubule dynamics inhibitor that shows potential for managing brain tumors, especially breast cancer brain metastases, due to its lower protein binding and resistance to P-glycoprotein extrusion.
  • A clinical study involved administering eribulin to cancer patients post-tumor removal, with samples analyzed to measure its concentrations in the brain and plasma.
  • Results indicated higher concentrations of eribulin in areas where the blood-brain barrier was disrupted, but overall levels in the brain were not enough to confirm consistent clinical effectiveness against brain tumors.
View Article and Find Full Text PDF

Pharmacokinetic (PK) elucidation of polymeric micelles delivering anticancer drugs is crucial for accurate antitumor PK-pharmacodynamic (PK-PD) simulations. Particularly, establishing a methodology to quantify the tumor inflow and outflow of anticancer drugs encapsulated in polymeric micelles is an essential challenge. General tumor biodistribution experiments are disadvantageous in that inflow quantification is easy, but outflow quantification is challenging.

View Article and Find Full Text PDF
Article Synopsis
  • Epilepsy, particularly temporal lobe epilepsy with hippocampal sclerosis (TLE-HS), affects over 70 million people worldwide and can become drug-resistant, prompting research into its underlying mechanisms.
  • This study focuses on the role of the xCT transporter in reactive astrocytes and how it is regulated by the YTHDC2 protein in the context of TLE-HS, using a mouse model induced by pilocarpine.
  • Through various molecular techniques, the research found that xCT enhances glutamate levels, promoting neuronal excitability and seizures, and that its expression is influenced by m6A modifications mediated by YTHDC2.
View Article and Find Full Text PDF

Objective: Targeting single monitoring modalities such as intracranial pressure (ICP) or cerebral perfusion pressure alone has shown to be insufficient in improving outcome after traumatic brain injury (TBI). Multimodality monitoring (MMM) allows for a more complete description of brain function and for individualized management. Transcranial Doppler (TCD) represents the gold standard for continuous cerebral blood flow velocity assessment, but requires high levels skill and time.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!